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Abstract
Retinal dopamine loss in Parkinson disease (PD) is reﬂected by visual neurophysiological dysfunction. We measured the thick-
ness of the circumpapillary retinal nerve ﬁber layer (RNFL) in PD patients using optical coherence tomography. The thickness in
the inferior quadrant of PD patients (147±20 microns) was signiﬁcantly thinner than that of controls (173±12 microns; p=0.002),
while the inferotemporal area was the thinnest (146±24 vs. 191±21 microns; p=0.0003). The results show signiﬁcant loss of RNFL
thickness in PD at speciﬁc sites.
 2004 Elsevier Ltd. All rights reserved.
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der associated with degeneration of dopaminergic neu-
rons in the substantia nigra. Besides its major
involvement in motor function, dopamine (DA) has
fully been established as a major neurotransmitter or
modulator in the retina (Djamgoz, Hankins, Hirano,
& Archer, 1997). Visual functions controlled at least
partially by dopamine, such as absolute sensitivity, spa-
tial contrast sensitivity, temporal sensitivity and color
vision are impaired in PD (Djamgoz et al., 1997; Bo-
dis-Wollner, 1990; Jackson & Owsley, 2003). The DA
content of the retina as measured at postmortem, is
low in PD patients (Harnois & Di Paolo, 1990). Data
concerning visual dysfunction in PD are based on neu-
rophysiological evaluation. It is unclear whether there
is concurrent tissue loss in the retina.0042-6989/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.visres.2004.06.009
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Ophir).Optical coherence tomography (OCT) is a non-inva-
sive, objective method, which can provide diagnostic in-
formation and quantitative data on biological tissues at
high resolution of 10 microns. The principle of OCT is
analogous to ultrasound, however, the system uses light
instead of acoustic waves. Standard circular OCT scans
(3.4-mm diameter) around the ONH provide objective
and reproducible measurements of the retinal nerve ﬁber
layer (RNFL) thickness, with a 6.9% coeﬃcient of vari-
ation between repeated scans in normal eyes (Blumen-
thal et al., 2000). Normal OCT ranges of the retina,
and measurements in diverse pathological conditions
of the optic nerve such as glaucoma and multiple sclero-
sis have been described (Parisi et al., 1999; Kanamori
et al., 2003). In glaucomatous eyes, regional reduction
in RNFL thickness and regional decreases in visual ﬁeld
(VF) sensitivity are topographically related. Further, the
magnitude of focal RNFL thinning is related to the
magnitude of decreased VF sensitivity (El Beltagi
et al., 2003).
We examined the thickness of the RNFL near its en-
try to the optic nerve head in PD patients and compared
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edge this has not been previously reported.1. Methods
1.1. Patients
Consecutive PD patients followed by our Movement
Disorders Clinic were recruited for the study. The crite-
ria for PD diagnosis were: (1) at least two of the follow-
ing signs: rest tremor, rigidity, bradykinesia, and
postural reﬂex impairment, (2) known sustained re-
sponse to antiparkinsonian medication and (3) no other
known or suspected causes for parkinsonism. Eyes with
posterior pole pathology such as macular degeneration,
those with optic neuropathies including glaucoma, glau-
coma suspect or patients with media opaciﬁcation such
as cataract that precluded precise ocular and OCT
examinations were excluded. Diagnosis of glaucoma
was based on any of the following: classical appearance
of the open angle glaucoma changes in the optic disc,
enlargement and especially vertical enlargement of the
optic cup, localized loss of disc rim and rim pallor,
asymmetry of cup/ disc ratio >0.2 between the two eyes,
baring of the lamina cribrosa, intraocular pressure and
typical visual ﬁeld loss.
Sixteen PD patients were initially recruited. Six were
excluded: four were unable to complete the OCT exam-
ination (dyskinesia, tremor, fatigue), one due to newly
diagnosed glaucoma, and one due to glaucoma suspect.
Only one eye of each of 10 patients was chosen for anal-
ysis as follows: when the OCT was successfully com-
pleted bilaterally, one eye at random was chosen
(n=6). When only one eye of the patient was reliably
examined, this eye was included in the study (n=4).
Ten age-matched controls were also examined; one eye
at random was chosen for analysis.1.2. Procedure
The Institutional Ethics Committee and Ministry of
Health approved the study. All subjects signed an
informed consent for participation. Each patient under-
went ocular examination, intraocular pressure measure-
ment and visual ﬁeld (VF) examination using the
Humphrey 24–2 visual ﬁeld program (Humphrey Instru-
ments, Pennsylvania). Each eye was examined by OCT,
with the pupil dilated. The subject was asked to ﬁxate a
luminous point; the required area was scanned by OCT.
The examination included ﬁve circumpapillary standard
circular scans (3.4 mm in diameter) followed by six ra-
dial lines centered at the optic nerve head (6 mm length
each).1.3. Statistical analysis
The RNFL thickness in four retinal quadrants,
namely: superior, inferior, nasal and temporal, in PD
patients was compared to that of age-matched control
subjects using Students t-test.2. Results
Ten PD patients (ﬁve males, aged 57±11 years
(mean±SD)), with disease duration of 7±4 years
(range, 2–15), and 10 age-matched healthy controls
(aged 52±7 years; p=0.22 vs. age of PD patients) partic-
ipated in the study. Patient characteristics, treatment
and mean circumpapillary RNFL thicknesses in four
quadrants are summarized in Table 1.
The RNFL thickness in the inferior retinal quadrant
of PD patients (147±20 microns) was signiﬁcantly thin-
ner than in control subjects (173±12 microns; p=0.002),
followed by the temporal quadrant (101±29 in PD vs.
126±11 in controls; p=0.019). Within the inferior quad-
rant, the RNFL was the thinnest in the inferotemporal
area (146±24 microns; Fig. 1a) as compared with con-
trols (191±21 microns; p=0.0003). Milder thinning
was observed at the mid-inferior site (154±29 vs.
186±24 microns, p=0.014). The thickness of the infero-
nasal part of the inferior quadrant was preserved
(131±33 in PD vs. 151±23 microns in controls,
p=0.119). The RNFL thinning was not correlated with
disease duration (Table 1).
The VF examination was reliably performed (ﬁxation
loss, false positive or false negative 625%) in ﬁve pa-
tients. Reduced sensitivity in the superior VF was de-
tected in four eyes, three of them with an arcuate
pattern and a superior nasal step in all four (Fig. 1b).
The reduction in VF sensitivity practically matched the
topography of RNFL thickness loss. Reduction of sen-
sitivity was also found in the inferior ﬁeld in one eye.
VF was normal in the ﬁfth eye.
The RNFL thickness at the inferotemporal site in PD
patients ranged between 108 and 185 microns (Table 1).
Individual values of control subjects were: 164, 167, 172,
180, 192, 196, 199, 204, 205, 232 microns. Ninety-ﬁve
percent (a=0.05) of the control subjects would be
expected to have an inferotemporal RNFL thickness
higher than a value that is calculated according to the
following formula:
X=mean inferotemporal RNFL thickness in con-
trols (t· standard deviation of the inferotemporal
thickness in controls); where t is taken from t-table based
on a degree of freedom of n1 (=9) and a=0.05. For our
control group, this value is: 191 (1.83·21)=153 mi-
crons. The inferotemporal thickness was >153 microns
in all control subjects and in only three of the 10 PD pa-
tients.
Table 1
Patient characteristics and circumpapillary RNFL thickness per quadrant and at the inferotemporal area
PD patients PD (duration years) Treatment Mean RNFL thickness (microns)
No. Symptom Superior Inferior Nasal Temporal Inferotemporal
1 T, B, R 2 S, A, DA 118 137 67 94 139
2 T, B, R 3 S, A 183 176 107 139 108
3 T, B, R 4 S, A, DA 175 139 123 105 143
4 T, B, R 4 S, A, DA 185 139 63 102 185
5 T, B, R 5 S, A, DA 168 131 94 152 172
6 T, B, R 6 S, A, DA, LD 155 162 150 66 138
7 T, B, R, P 6 A, LD, DA 140 148 104 76 115
8 T, B, R, P 10 A, LD, DA 167 172 124 102 160
9 T, B, R, P 13 A, LD, DA 140 111 39 69 158
10 T, B, R 15 A, LD, DA 170 151 117 100 142
Group mean±SD 160±22 147±20** 99±34 101±29* 146±24***
Total retinal thickness (125±31 microns)
Control subjects
Group mean±SD 154±16 173±12 117±19 126±11 191±21
(Range) (137–173) (153–192) (92–147) (103–143) (164–232)
Total retinal thickness (143±26 microns)
Asterisks depict signiﬁcant diﬀerence from controls *p=0.019, **p=0.002, ***p=0.0003.
PD patients are aligned in increasing order of disease duration. T=Tremor, B=bradykinesia, R=rigidity, P=postural disturbance. S=Selegiline,
A=Amantadine, LD=L-dopa, DA=dopamine agonist.
Fig. 1. Patient 10, right eye. (a) The RNFL thickness (in microns) is shown by the dark line in the graph, and per clock-hour and quadrants in circles.
The gray area represents the normal age-matched algorithm. As depicted in the numerical presentation, the inferotemporal RNFL thickness was 142
microns in this patient (mean inferotemporal thickness of the control group was 191±21, range 164–232 microns). (b) Visual ﬁeld examination.
Reduced sensitivity is detected mainly in the superior ﬁeld in an arcuate fashion (mean deviation0.29 decibels and pattern standard deviation 2.21
decibels).
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These results suggest signiﬁcant reduction in the in-
ferotemporal circumpapillary RNFL in PD patients.
Seventy percent of the PD patients had an inferotempo-
ral RNFL thickness <153 microns, whereas all control
measurements exceeded this value. Milder relative thin-
ning was also encountered at the mid-inferior site and
the temporal quadrant.
The primary visual impairment in PD is due to dop-
aminergic loss in the retina; however, this depletion may
have downstream eﬀects (Jackson & Owsley, 2003). Ret-
inal DA deﬁciency is believed to alter visual processing
by modiﬁcation of receptive ﬁeld properties of ganglion
cells, (Djamgoz et al., 1997) whose axons form the
RNFL. It is noteworthy that when a color vision ab-
normality is detected in PD, it usually involves blue-sen-
sitive cones (Bodis-Wollner, 1990; Djamgoz et al., 1997;
Jackson & Owsley, 2003). The function of the S-cone
(blue) system is also reduced in cocaine-dependent pa-
tients, consistent with inhibition of the DA transporter
by cocaine (Roy, Roy, Williams, Weinberger, & Smel-
son, 1997).
The synaptic structuring of the changes in the recep-
tive ﬁelds of ganglion cells and the degree of their sus-
ceptibility to dopaminergic degeneration is not known
in detail (Djamgoz et al., 1997). Neurophysiological
abnormalities in the retina of PD patients are diﬃ-
cult to follow due to the confounding eﬀect of treat-
ment (Djamgoz et al., 1997). There is accumulated
evidence that visual impairment progresses with motor
disability in PD and ﬂuctuates in parallel with motor
ﬂuctuations (Bodis-Wollner, 2002; Diederich, Raman,
Leurgans, & Goetz, 2002). The exact loci of this impair-
ment remain unclear. Questions are raised as to the role
of retinal dopaminergic deﬁcits in PD and/or the invol-
vement of hierarchically higher pathways (Bodis-Woll-
ner, 2002). Dopamine is enrolled in the modulation of
the receptive ﬁelds of ganglion cells through D1 and
D2 receptors via feedback by establishing the gain of
ganglion cells in the monkey and human retina (Bodis-
Wollner & Tzelepi, 1998). Visual impairment is also
observed in the animal model of PD using MPTP
(1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine) where
the retina shows dopaminergic deﬁciency with loss of a
subset of retinal amacrine cells (Bodis-Wollner, 1990;
Tatton, Kwan, Verrier, Seniuk, & Theriault, 1990),
which provide input to ganglion cells. Dopamine is also
important in controlling the eﬃciency of other neuro-
chemical systems such as glutamate, GABA and glycine
in the retina. Dysfunctions that result from DA deple-
tion may involve long-term complex synaptic eﬀects.
It is possible that impoverished dopaminergic input to
a subset of ganglion cells, contributes to abnormal
production of glutamate and atrophy of these selected
ﬁbers.Reduction in sensitivity in the visual ﬁelds in ob-
served in these series, matches topographically the
localized thinning of the RNFL, as previously discussed
in other diseases where RNFL damage occurs (El Belt-
agi et al., 2003). It could be argued that some of the
superior scotomas could be the expression of an edge
artifact by the superior eyelid. However, the arcuate
conﬁguration and the relatively low intensity of the
sensitivity reduction are strongly suggestive of localized
nerve ﬁber bundle defect (Anderson, 1992).
The distribution of the individual thicknesses in PD
patients was lower than in controls. Although a deline-
ative value of thickness could be calculated, further
studies in larger series are mandatory to evaluate the
possibility to deﬁne cut-oﬀs that could serve clinical pur-
poses.Acknowledgment
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